Daewoong to maximize Olmetec sales
Published: 2008-03-19 06:57:00
Updated: 2008-03-19 06:57:00
Daewoong Pharm and Daiichi Sankyo Korea plan to co-promote Olmetec (olmesartan medoxomi), a selective AT1 subtype angiotensin II receptor antagonist, from April 1. Olmetec, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract.
Through this strategic co-promo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
